New clinical collaboration and co-development with Federal University of São Paulo

We are very pleased to announce yet another clinical trial and co-development collaboration, and this time it is the research group of Associate Professor Henrique Ballalai Ferraz of Federal University of São Paulo. Together we will further develop and test Stardots´ ANLIVA platform for digital biomarkers. Stardots is looking to enter the Brazilian market in the coming years, and local clinical trials and we are actively looking for partners to ensure best possible product market fit. This is the core Stardots´ Go-To-Market strategy.

Henrique is currently an Associate Professor at the Federal University of São Paulo. He was previously the President of the Panamerican Section of the International Society of Parkinson’s Disease and Movement Disorders from 2017 to 2019, Coordinator of the Teaching Committee of the Brazilian  Academy of Neurology from 2016-2020 and is now a Consultant of the Technical Chamber of Neurology and Neurosurgery of CREMESP. He has experience in Neurology, working mainly on the following subjects: Parkinson’s disease, dystonia, tics, tardive dyskinesia and chorea.

We expect the trials to start during the spring of 2023 after approval from ANVISA. The modules to be tested are ANLIVA – Dyskinesia and ANLIVA – Eye Movement for symptom quantification of movement disorders and eye-motor control. The end goal is to obtain a fast, reliable and objective digital biomarker and to increase quality of life and decrease cost to society. We are looking forward to the collaboration and to launch our ANLIVA platform to the Brazilian market.